Danish biotech company raises €20 million: Closing in on clinical trials

Biograil announced the closing of the financing round, with investments from Verve Ventures, Megatrend Invest and the HTGF fund.

The additional funds of €20 million will support ongoing preparations for the planned phase I clinical trial of its product, BIONDD, a new drug delivery platform.

“Excellent to see such strong support from existing internal investors and involve the HTGF Opportunity growth fund in the round. This, in combination with non-diluting funding from partnerships, will enable Biograil to continue to move our BIONDD technology toward Phase 1 clinical studies,” Biograil CEO Karsten Lindhart said in a press release.